Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare’s new pilot program offering GLP-1 weight-loss drugs at a reduced $50 monthly cost is providing relief to some beneficiaries, but others with qualifying medical conditions are being left behind. The initiative, launched in July by the Centers for Medicare & Medicaid Services (CMS), covers medications such as Wegovy, Zepbound, and Foundayo for eligible Medicare Part D enrollees with obesity or related health risks. However, patients with diagnoses like Type 2 diabetes or obstructive sleep apnea—conditions for which GLP-1 drugs are also FDA-approved—are excluded from the discounted pricing and must rely on standard Part D coverage, often facing hundreds of dollars in monthly copays.

Jeff La Marca of Basking Ridge, New Jersey, found himself in this exact situation. The 68-year-old, who has morbid obesity and a history of heart disease, was denied enrollment in the pilot program despite meeting weight criteria. His severe obstructive sleep apnea, which qualifies him for GLP-1 treatment under Medicare Part D, disqualifies him from the $50 pricing option. Without coverage, La Marca cannot afford the $750 monthly cost of Zepbound, leaving his prescription unfilled.

The Medicare GLP-1 Bridge program was designed as an 18-month pilot to assess whether subsidizing these drugs for weight management could lead to long-term savings by preventing obesity-related complications. Eligibility requires a BMI of 35 or higher, or a BMI of 27 to 34 with additional conditions like cardiovascular disease or prediabetes. While CMS reports that prior authorization requests are processed quickly—often within 12 hours—only those using the drugs solely for weight loss qualify for the $50 rate. Patients with other approved medical uses face standard Part D cost-sharing rules, which vary widely and can be prohibitive.

Juliette Cubanski, director of the Program on Medicare Policy at KFF, estimates that 3.8 million people qualify for the pilot, with potential program costs ranging from $3.3 billion to $10 billion depending on enrollment levels. Expanding eligibility further could add billions more in federal spending. The CMS has not released detailed cost projections but notes that the program has enabled thousands of beneficiaries to access GLP-1 medications at a reduced price.

Healthcare providers like Taylor Lacy, a primary care physician in Kansas, warn that the program’s restrictions may prevent those with the greatest medical need from benefiting fully. “Coverage doesn’t always mean affordable,” Lacy noted, pointing to common barriers such as prior authorization and step therapy requirements that delay or deny access to these medications. Insurance industry representatives, including trade group AHIP, attribute high out-of-pocket costs to drug manufacturers’ pricing decisions.

For now, patients like La Marca remain in limbo, caught between affordability barriers and medical necessity. As he continues to appeal denials and explore alternatives, his frustration underscores the gap between policy intent and real-world access.

#Medicare #GLP1 #WeightLossDrugs #HealthcareCosts #Zepbound #Wegovy #CMS #KFFHealthNews